Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

Lead Discovery Center GmbH. (10/11/23). "Press Release: LDC and JT Team Up for the Discovery of New Therapies". Dortmund.

Organisations Organisation Lead Discovery Center GmbH (LDC)
  Group Max Planck Society for the Advancement of Science
  Organisation 2 Japan Tobacco Inc. (JT)
  Group Japan Tobacco (Group)
Products Product drug discovery services
  Product 2 drug discovery
Index term Index term Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network
Persons Person Fujimoto, Muneaki (Japan Tobacco 202310 President of JT Pharmaceutcial Business)
  Person 2 Klebl, Bert (Lead Discovery Center 200806– CEO)

The Lead Discovery Center GmbH (LDC) and Japan Tobacco Inc. (JT) have closed a collaboration agreement to discover new first-in-class therapeutic approaches, focusing around novel chemical entities for the treatment of various diseases with significant unmet medical need.

Over a period of up to seven years, LDC, together with its extensive academic network, will identify high-potential projects that fit JT’s therapeutic priorities and in-licensing needs. The network includes research institutes of the Max Planck Society, other research organizations, as well as high-profile universities from all over Germany and beyond. Ideas for new therapeutic approaches will be collaboratively incubated at LDC as usual, although with additional support and expertise from JT. After achieving the proof-of-concept milestone by demonstrating in vivo efficacy for representatives of the respective new compound class, such projects will be targets for in-licensing by JT, where they will be further developed.

“We are pleased to team up with the LDC and its excellent network of academic inventors. The collaboration will enable us to identify truly novel therapeutic approaches that could make a meaningful difference in the lives of patients around the world”, says Muneaki Fujimoto, President of JT’s Pharmaceutical Business.

“We are excited to have a new industry partner on board who shares our brave ambition and the associated risks to transfer highly innovative approaches from academic research into application”, Bert Klebl, CEO and CSO of LDC, continues. “With their proven expertise in business and drug development, JT is perfectly positioned to advance early-stage projects along the value chain, and ultimately towards patients who urgently need new therapeutic options. We are looking forward to a productive and exciting collaboration.”

Academic inventors and their institutions will not only benefit from the drug discovery and development experience of both LDC and JT, but also from future commercialization revenues.



Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Phone: +49 231 97 42 70 00


About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.

LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, KinSea AS, HLB Life Science, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information at

About JT

JT has a pharmaceutical business that focuses on research and development, manufacturing and sales of prescription drugs.

Further information at

Record changed: 2024-01-06


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Max Planck Society for the Advancement of Science

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px

» top